CVS Health Corp vs DoorDash Inc — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while DoorDash Inc trades at $192.17 (market cap $82.86B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and DoorDash Inc for 59 Days on average.
| CVS | DASH | |
|---|---|---|
Market Cap | $112.49B | $82.86B |
Volume | 8,467,392 | 2,006,669 |
Sector | Health | Media |
52-Week High | $110.60 | $275.44 |
52-Week Low | $70.08 | $146.60 |
Typical Hold Time | 83 Days | 59 Days |
Enterprise Value | $174.83B | $80.82B |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
DoorDash (DASH) trades at $191.71, down 0.99% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, though mixed quarterly earnings and a fraud investigation present near-term headwinds.
The outlook remains positive given DoorDash's market leadership and expansion into retail delivery, but investors face risks from competitive pressures, regulatory scrutiny, and elevated valuation multiples. With current price near analyst targets and technical indicators showing bullish momentum, the stock offers growth potential balanced against execution risks in a competitive delivery market.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →